Individual Investor

Hans GCP Schikan

Signal active

Chief Executive Officer

Bio

Hans GCP Schikan, Chief Executive Officer is responsible for the overall management and strategic direction of Prosensa. He has more than 20 years senior managerial experience in the pharmaceutical and biotech industry.

Before joining Prosensa in January 2009, he was VP Global Marketing and Strategic Development for Genzyme’s rare genetic disease franchise. In this position he oversaw the launch of various orphan drugs globally.

Prior to Genzyme, Hans worked at Organon in various senior business roles and across different geographies, including managing director positions in multiple countries. Hans holds a PharmD degree from the University of Utrecht, The Netherlands.

Location

Amsterdam, Noord-Holland, The Netherlands, Europe

Social

Primary Organization

Prosensa

Founded

2002

Investment

Lead investment

Exits

Employees

11-50

Industry

Biotechnology, Health Care, Medical, Therapeutics, Genetics

Jobs history

Swanbridge Capital

Chair of the Investor Board

2017 - Current

VectivBio

Member of the Board of Directors

2019 - Current

Top Team Member Top Sector Life Sciences & Health

2012 - Current

Complix

Chair of the Board of Directors

2015 - Current

Chairman Of The Board

2021 - Current

Member of the Board of Directors

2018 - Current

InteRNA Technologies

Chair of the Supervisory Board

2015 - Current

Co-Founder and Vice Chairman of the Board

2015 - Current

Board and Advisor Roles

N/A

Invest in regions

Profile Resume

Hans GCP Schikan is the Chief Executive Officer at Prosensa, based in Europe. With a background in Biotechnology, Hans GCP Schikan has a rich history of leadership and innovation. Hans GCP Schikan studied unknown unknown @ Utrecht University. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.

Recommendation from your interest